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Abstract
Background: The reliable prediction of hepatocellular carcinoma (HCC) recurrence patterns potentially
allows for the prioritization of patients for liver resection (LR) or transplantation.
Objectives: The aim of this study was to analyse clinicopathological factors and preoperative Milan
criteria (MC) status in predicting patterns of HCC recurrence.
Methods: During 1992–2012, 320 patients undergoing LR for HCC were categorized preoperatively as
being within or beyond the MC, as were recurrences.
Results: After a median follow-up of 47 months, 183 patients developed recurrence, giving a 5-year
cumulative incidence of recurrence of 62.5%. Patients with preoperative disease within the MC had better
survival outcomes than those with preoperative disease beyond the MC (median survival: 102 months
versus 45 months; P < 0.001). Overall, 31% of patients had preoperative disease within the MC and 69%
had preoperative disease beyond the MC. Estimated rates of recurrence-free survival at 5 years were
61.8% for all patients and 53.8% for patients with initial beyond-MC status. Independent factors for
recurrence beyond-MC status included preoperative disease beyond the MC, the presence of
microsatellite or multiple tumours and lymphovascular invasion (all: P < 0.001). A clinical risk score was
used to predict survival and the likelihood of recurrence beyond the MC; patients with scores of 0, 1, 2
and 3 had 5- year incidence of recurring beyond-MC of 9.0%, 29.5%, 48.8% and 75.4%, respectively (P
< 0.0001).
Conclusions: Regardless of initial MC status, at 5 years the majority of patients remained disease-free
or experienced recurrence within the MC after LR, and thus were potentially eligible for salvage trans-
plantation (ST). Incorporating clinicopathological parameters into the MC allows for better risk stratifica-
tion, which improves the selection of patients for ST and identifies patients in need of closer surveillance.
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Introduction
Hepatocellular carcinoma (HCC) is the sixth most common
cancer worldwide and one of the leading causes of cancer-related
death.1 Its incidence in the USA has tripled over the last 20 years
and is related to the dramatic increases in hepatitis C virus-related
and alcoholic liver disease.2 Surgery, either liver resection (LR) or
orthotopic liver transplantation (OLT), remains the standard of
care in the curative treatment of HCC.3 Liver resection is the
treatment of choice for patients with HCC without cirrhosis and
provides excellent early and longterm results.4 The care of HCC
patients was revolutionized after Mazzaferro et al. demonstrated
in 1996 that patients with up to three HCC nodules, each of <3 cm
in size, or one tumour of <5 cm, without vascular invasion or
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extrahepatic spread [factors that became known as the ‘Milan
criteria’ (MC)] experienced a 5-year overall survival (OS) rate
comparable with that in patients with end-stage liver cirrhosis
undergoing transplant without cancer (75%).5 The MC is the
current benchmark for selecting HCC patients for OLT: it has
been validated in many studies including a recent meta-analysis,
and is used by the United Network for Organ Sharing (UNOS)
and most transplant centres.5–8
In theory, OLT represents an ideal choice for patients with
cirrhosis and HCC because it treats the underlying liver disease as
well as the tumour and is associated with fewer recurrences than
resection. However, long waiting lists due to the lack of suitable
donor organs, the potential for tumour progression beyond the
MC while awaiting transplantation and problems related to life-
long immunosuppression weaken its potential benefits.9,10 Indeed,
when intention-to-treat analysis is used, resection and OLT
appear to have comparable longterm survival rates.7,9,11,12
The strategy of utilizing LR as the initial treatment option in
transplant-eligible HCC patients and employing salvage trans-
plantation (ST) for HCC recurrences is both reasonable and
attractive. Recent studies have shown promising results from com-
bining these two primary therapeutic modalities, utilizing resec-
tion as the first-line intervention and reserving transplantation
listing (for ST) for patients who show favourable histo-
pathological features following resection, or in the event of recur-
rence within the MC.11,13–18 Most of these studies have involved
patients with tumours within the MC on a background of cirrho-
sis. At the same time, adverse histopathological features, such as
vascular invasion, poor differentiation, high-grade disease and
microsatellitosis, are known to increase as the tumour size and
number increase beyond the MC.12,19,20 Additionally, recent
reports have identified several independent clinicopathological
risk factors for HCC recurrence, such as serum albumin level,
indocyanine green retention rate at 15 min (ICG R15), anatomical
resection, tumour number, vascular invasion, beyond MC status
and prior transcatheter arterial chemoembolization (TACE).21,22
This study investigated the relationship between preoperative
MC status and HCC recurrence in a surgical cohort comprising
patients with advanced-stage tumours arising mostly in non-
cirrhotic livers. It also investigated clinicopathological features
predictive of patterns of recurrence which can enhance the ability
of the MC to identify patients with unfavourable biology, who
might be candidates for ST or might perhaps be better served by
initial transplantation. Based on this analysis, a risk model was
generated.
Materials and methods
Patient selection and preoperative assessment
Patients with HCC who underwent LR with curative intent and
negative surgical margins at Memorial SloanKettering Cancer
Center (MSKCC), between January 1992 and January 2012, were
identified from a prospective database. Patients with fibrolamellar
HCC or mixed hepatocellular–cholangiocarcinoma cancers were
excluded. Similarly, patients who underwent ablation only
without LR and patients who underwent LR at an outside facility
were excluded. Medical records were reviewed for clinical and
pathological variables including age, gender, body mass index
(BMI), American Society of Anesthesiologists (ASA) score,
comorbidities (such as liver cirrhosis, aetiology of liver disease,
hepatitis status), laboratory results [e.g. serum albumin, bilirubin,
platelet count, liver function, α-fetoprotein (AFP)], prior treat-
ment (e.g. TACE, prior LR/ablation), preoperative tumour size
and number, operative data (type of LR, blood loss/transfusion,
operative time, additional procedures), pathological data
(tumour size, microsatellites, margins, tumour differentiation,
lymphovascular invasion), and recurrence and survival data.
Approval for the study was obtained from the MSKCC institu-
tional review board.
The preoperative management of patients was discussed at
weekly multidisciplinary hepatopancreatobiliary (HPB) disease
management conference which included HPB surgeons, medical
oncologists, diagnostic and interventional radiologists, and gas-
troenterologists. Criteria for resectability included anatomically
resectable disease with an adequate future liver remnant (FLR)
reserve, the absence of distant metastases and the absence of main
portal vein and inferior vena cava tumour thrombus. The preop-
erative assessment of patients included a complete history and
physical examination, complete blood count and metabolic panel,
liver function panel, coagulation profile and AFP level. Routine
imaging consisted of a triphasic computed tomography (CT) or
magnetic resonance imaging (MRI) of the liver and a CT of the
chest as part of the metastatic workup. Volumetry by CT was
performed in selected patients in whom concerns regarding FLR
volume, based on the extent of the planned resection, existed.
Patients were considered positive for hepatitis B virus if they had
hepatitis B surface antigen or anti-hepatitis B core antibody, and
considered positive for hepatitis C virus if they had anti-hepatitis
C virus antigen.
Patients were assessed according to the MC at their initial pres-
entation and at any recurrence. Patients were stratified by MC
status based on preoperative imaging. Microsatellites were deter-
mined by histopathological examination; the presence of multiple
tumours was based on preoperative cross-sectional imaging.
Surgical resection and histopathology
All resections were performed using a standard technique as
reported previously.23 Intraoperative ultrasonography was rou-
tinely performed to detect additional tumours in the liver, to
delineate the relationship of the tumour to major vascular struc-
tures, and to guide the plane of parenchymal transection. Resec-
tions were either anatomic or limited according to the severity of
cirrhosis and the location(s) of the tumour(s). An intermittent
Pringle manoeuvre was used selectively; especially in major resec-
tions. Major resections were defined using the International
Hepatopancreatobiliary Association (IHPBA) Brisbane classifica-
tion as consisting of three or more Couinaud liver segments.24 The
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diagnosis of HCC was confirmed pathologically in all patients.
The histopathological features of the tumour(s), including
number, size of the greatest lesion, lymphovascular invasion, sat-
ellite lesions, and presence of cirrhosis were recorded. Tumours
were graded as being well, moderately or poorly differentiated.
Follow-up and recurrences
After the initial postoperative outpatient visit, the follow-up
schedule consisted of office visits every 3–4 months in the first 2
years and every 6 months thereafter, during which physical exami-
nation, liver function tests, AFP levels and CT and/or MRI were
routinely performed. Recurrences were either biopsy-proven or
evidenced on radiology (according to the typical appearance on
CT or MRI of new imaging findings that progressed in serial
imaging). The date of recurrence was recorded as the date of any
radiological study identifying new findings, and the type of recur-
rence was classified as being within or beyond the MC and rec-
orded. Recurrence-free survival (RFS) and OS were calculated
from the date of LR until tumour recurrence or patient death/last
follow-up, and from the date of LR until patient death/last follow-
up, respectively. Sites of initial disease recurrence were also rec-
orded and liver-only disease was distinguished from extrahepatic
recurrences.
Recurrences were treated using a variety of techniques, mainly
re-resection and interventional radiology-guided radiofrequency
ablation, microwave ablation, ethanol injection or transarterial
embolization (TAE). Treatment decisions for recurrent disease
were discussed during a multidisciplinary disease management
team conference. Medically fit patients who developed recurrence
were offered re-resection if the disease was resectable and in the
absence of contraindications (i.e. an adequate liver remnant,
absence of multifocal disease, absence of extrahepatic metastases,
etc.). Other locoregional treatments, such as TAE and/or ablation,
were offered to patients in whom resection was inappropriate but
ablative therapy was technically feasible. Systemic therapy, such as
treatment with sorafenib (Nexavar™; Bayer HealthCare Pharma-
ceuticals, Inc., Whippany, NJ, USA) or treatment on clinical trials,
was generally offered to selected patients with extrahepatic recur-
rence. Patients considered to be suitable transplant candidates
were referred to a transplant centre for further evaluation.
Statistics
Disease and treatment characteristics were summarized using the
frequency and percentage for categorical covariates, and the
median and range for continuous covariates, and compared using
Fisher’s exact test and the Wilcoxon rank-sum test. Cumulative
incidences of recurrence within the MC, recurrence beyond the
MC and death without recurrence were estimated using compet-
ing risks methods and compared using Gray’s test, and Fine and
Gray regression. A composite variable representing the presence of
either microsatellites based on pathology or multiple tumours
based on preoperative imaging was created because it was thought
that definitions of each of these may be subjective but the presence
of either was more objective. Variables significantly associated
with recurrence beyond the MC on univariate analysis were
entered into a multivariate model, and backward elimination was
used to reduce the model size. In the final model, the hazard ratios
associated with recurrence beyond the MC for all three remain-
ing significant risk factors (initial disease beyond the MC,
microsatellites or multiple tumours, and lymphovascular inva-
sion) were very similar (ranging from 2.22 to 2.48), and this
allowed the development of a simple clinical risk score (CRS) in
which 1 point was assigned to each risk factor without weighting,
which resulted in the creation of four distinct risk groups. Overall
survival and RFS were estimated using Kaplan–Meier methodol-
ogy and compared using the log-rank test. All statistical analyses
were performed using sas Version 9.2 (SAS Institute, Inc., Cary,
NC, USA) or R Version 3.0.1 (R Foundation for Statistical Com-
puting, Vienna, Austria) using the cmprsk package. All P-values
were two-sided. P-values of <0.05 were considered to indicate
statistical significance.
Results
Clinicopathological characteristics
The study cohort consisted of 320 consecutive patients who
underwent elective partial hepatectomy for HCC with negative
surgical margins between January 1992 and January 2012 at
MSKCC. After the exclusion of patients who died (n = 13; eight
before 2000) or were lost from follow-up (n = 3) within 90 days,
304 patients remained for cohort analysis and 295 patients for
recurrence pattern analysis (nine patients were of unknown recur-
rence status). The median age of the patients was 67 years (range:
14–89 years) and 89 (29%) were female. The majority of patients
were of ASA class 2 status (48%) or class 3 or 4 status (51%).
Median preoperative AFP was 21 ng/ml (range: 1–374 000 ng/ml).
Mean preoperative serum bilirubin was 0.7 mg/dl (range: 0.2–
11.3 mg/dl) and mean albumin was 4.2 g/dl (range: 2.3–5.1 g/dl).
Overall, preoperatively, 210 (69%) patients harboured tumours
beyond the MC. A total of 147 (48%) patients underwent a major
hepatic resection; the median estimated blood loss was 400 ml
(range: 10–8500 ml).
On histopathology, median tumour size was 6.6 cm (range:
0.9–25.5 cm). Most patients had solitary tumours (88%), and
were moderately or poorly differentiated (83%). Approximately a
quarter of the patients (24%) had cirrhosis. The median follow-up
period in event-free patients was 47 months (range: 6−200
months). Tumour recurrence data were available in 295 patients,
of whom 183 (62%) developed recurrence; the 5-year cumulative
incidence of recurrence was 62.5% for the entire cohort. The
cohort characteristics are summarized in Table 1.
Preoperative MC status and recurrence patterns
Table 1 represents a comparison of clinical, surgical and patho-
logical data for patients classified with preoperative disease within
the MC (n = 94, 31%) or beyond the MC (n = 210, 69%). There
was no difference in demographic characteristics between the two
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groups. Patients of beyond-MC status had larger tumours (9.0 cm
versus 3.2 cm; P < 0.001), necessitating major resections more
frequently (63% versus 16%; P < 0.001) and, therefore, experi-
enced greater estimated blood loss (500 ml versus 300 ml; P <
0.001). These tumours more often had adverse histopathological
characteristics, namely more frequent lymphovascular invasion
(52% versus 34%; P = 0.004), microsatellites (24% versus 14%;
P = 0.05) and poor differentiation (30% versus 16%; P = 0.03).
Table 1 Demographic and disease data for patients with preoperative disease within and beyond the Milan criteria (MC)
Factors Whole cohort
(n = 304)
Within MC groupa
(n = 94)
Beyond MC groupa
(n = 210)
P-valuea
Demographic data
Female gender, n (%) 89 (29%) 25 (27%) 64 (30%) 0.6
Age, years, median (range) 67 (14–89) 67 (32–85) 67 (14–89) 0.6
MELD score, median (range) 8 (6–19) 8 (6–13) 8 (6–19) 0.334
Child–Pugh score, median (range) 5 (5–8) 5 (5–6) 5 (5–8) 0.007
Child–Pugh Grade A, n (%) 236 (97%) 70 (100%) 166 (96%) 0.1973
Child–Pugh Grade B, n (%) 7 (3%) 0 7 (4%) –
Child–Pugh Grade C, n (%) 0 0 0 –
Operative data
Prior liver resection, n (%) 12 (4%) 9 (10%) 3 (1%) 0.002
Major resection, n (%) 147 (48%) 15 (16%) 132 (63%) <0.001
Blood loss, ml, median (range) 400 (10–8500) 300 (10–3000) 500 (25–8500) <0.001
Pathological data
Tumour size, cm, median (range) 6.6 (0.9–25.5) 3.2 (0.9–13) 9 (1–25.5) <0.001
Single tumour, n (%) 267 (88%) 86 (91%) 181 (86%) 0.3
Differentiation, n (%) 0.03
Well 51 (17%) 17 (18%) 34 (17%)
Moderate 168 (57%) 60 (65%) 108 (53%)
Poor 77 (26%) 15 (16%) 62 (30%)
Lymphovascular invasion, n (%) 141 (46%) 32 (34%) 109 (52%) 0.004
Microsatellites present, n (%) 63 (21%) 13 (14%) 50 (24%) 0.05
Cirrhosis present, n (%) 74 (24%) 35 (37%) 39 (19%) <0.001
Within Milan criteria by pathology – 88 (94%) 19 (9%) <0.001
Survival, months, median (range) – 102.1 (67.3–127.0) 44.9 (36.1–63.5) <0.001
RFS, months, median (range) – 45.6 (28.8–66.2) 15.0 (10.2–22.1) <0.001
Aetiology of primary liver disease, n (%) <0.001
Alcohol 32 (11%) 14 (15%) 18 (9%)
Haemochromatosis 6 (2%) 2 (2%) 4 (2%)
Hepatitis B 79 (26%) 29 (31%) 50 (24%)
Hepatitis B and C 1 (0.3%) 1 (1%) 0
Hepatitis C 52 (17%) 26 (28%) 26 (12%)
Non-alcoholic steatohepatitis (NASH) 1 (0.3%) 0 1 (0.5%)
None 133 (44%) 22 (23%) 111 (53%)
Recurrence pattern, n (%) NA
Recurrence within MC – 27 (29%) 45 (22%)
Recurrence beyond MC
(extrahepatic recurrence)
– 17 (19%) 94 (46%)
(11/17) (63/94)
No evidence of disease – 48 (52) 64 (32%)
Unknown recurrence status – 2 (2%) 7 (3%)
aThe univariate analysis was performed for the within-MC and beyond-MC groups only, not for the whole cohort (whole cohort, n = 304: descriptive
data only).
MELD, Model for End-stage Liver Disease; NA, not applicable; RFS, recurrence-free survival.
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Figure 1 represents a flow chart of the cohort and the recurrence
patterns based on the MC status of patients. Patients with HCC
initially within the MC (31% of the cohort) had longer median OS
compared with patients of initial beyond-MC status (69% of the
cohort) (102 months versus 45 months; P < 0.001) and longer
median RFS (46 months versus 15 months; P < 0.001) (Fig. 2a, b).
Patients with HCC initially within the MC (31% of the cohort)
were more likely to be alive and disease-free at 5 years than those
with initial disease beyond the MC (69% of the cohort) (42%
versus 21%; P < 0.0001). Patients with HCC initially within the
MC were less frequently subject to recurrence beyond the MC
(5-year cumulative incidence: 19.9% versus 46.2%) and more fre-
quently subject to recurrence within the MC (5-year cumulative
incidence: 30.9% versus 21.4%) than patients with initial disease
beyond the MC (Fig. 3a, b).
In patients who died without evidence of recurrence (n = 32)
(Fig. 1), causes of death were liver failure (n = 4), non-HCC malig-
nant disease (n = 7), and medical illness (myocardial infarction,
cerebrovascular accident) (n = 3); in 18 patients, the cause of death
was multifactorial or unknown.
Treatment of recurrences
Treatment options for HCC recurrences included re-resection,
locoregional therapy such as TAE and/or ablation, and systematic
therapy with best supportive care. Suitable transplant candidates
were referred to a transplant centre for evaluation. This decision-
making process was based on a multidisciplinary team discussion.
Of the patients who had recurrences within the MC and for
whom good follow-up and treatment data were available (n = 68 of
72 patients with recurrences within the MC), 50% underwent TAE
only, 18% underwent re-resection, 16% were treated with combi-
nation therapy of TAE and ablation, and 4% underwent ablation
only. Overall, five patients (7%) were referred for transplantation
evaluation and three (4%) of these were eventually transplanted.
Remaining patients (5%) received best supportive care.
Of the patients in whom recurrences were beyond the MC
and for whom good follow-up and treatment data were available
(n = 65), 48% underwent TAE, 18% received systemic therapy
(e.g. sorafenib), 9% underwent re-resection, 5% were treated with
a combination of TAE and ablation, and the remaining 20%
received best supportive care.
Incorporating clinicopathological characteristics into
the MC
Clinical and pathological data are summarized in Table 1. The
clinicopathological variables were analysed to predict three differ-
ent patterns of (non-)recurrence: (i) recurrence within the MC;
(ii) recurrence beyond the MC, and (iii) death without recurrence.
On univariate analysis, initial disease beyond the MC, gender,
major resection, blood loss, tumour size, lymphovascular inva-
sion, microsatellites and the presence of multiple tumours were
significantly associated with recurrence beyond the MC. None of
the clinicopathological variables including the aetiology of the
primary liver disease were significantly associated with recurrence
Figure 1 Recurrence patterns according to Milan criteria (MC) status in 304 patients with hepatocellular carcinoma
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within the MC or death without recurrence (except for age in
patients who died without recurrence) (Table 2). In the 94
patients in whom disease was classified as within the MC on
preoperative imaging, six (6%) had disease beyond the MC on
pathology (pMilan). Of the 210 patients with preoperative disease
beyond the MC, 19 (9%) were found to be within pMilan status.
The concordance of preoperative MC based on imaging and
pMilan was very high, and the statistical significance was
Figure 2 Overall survival (OS) and recurrence-free survival (RFS) by initial Milan criteria (MC) status and clinical risk score (CRS) in 295
patients with hepatocellular carcinoma
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Figure 3 Cumulative incidences of recurrence stratified by the Milan criteria (MC) and clinical risk score (CRS) based on preoperative MC
status in 295 patients with hepatocellular carcinoma. (a) preoperatively within Milan criteria; (b) preoperatively beyond Milan criteria
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preserved in the multivariate analysis regardless of whether
preoperative MC or pMilan was used; the effect sizes of preopera-
tive MC and pMilan on recurrence outside the MC were identical.
Therefore, preoperative MC status based on imaging was used in
the present risk model as it is based on preoperative imaging and
is therefore more clinically relevant.
A multivariate analysis was performed based on the significant
risk factors. Initial disease beyond the MC, and the presence of
microsatellites or multiple tumours and lymphovascular invasion
remained independent risk factors for the prediction of recurrence
beyond the MC (Table 2). Other important known risk factors,
such as AFP and tumour differentiation, which were of borderline
significance (P < 0.1), were each added to the final model but were
not independent predictors and were therefore eliminated.
Risk model for the prediction of recurrence beyond
the MC
Based on this multivariate analysis, a CRS was devised to predict
the recurrence of HCC beyond the MC. The cumulative inci-
dences of recurrence beyond the MC in these risk groups are
shown in Fig. 3c. Patients with a score of 0 had 1-, 3- and 5-year
incidences of recurrence beyond the MC of 0%, 6.5% and 9.0%,
respectively, whereas patients with a score of 3 had significantly
higher 1-, 3- and 5-year incidences of recurrence beyond the MC
of 63.6%, 75.4% and 75.4%, respectively (P < 0.0001). This analy-
sis was repeated for the cohort of patients of within-MC status, in
whom the CRS was found to be significantly associated with a
higher incidence of recurrence beyond the MC (P = 0.002)
(Fig. S1, online)
Based on this CRS, patients with a score of 0 had 1-, 3- and
5-year OS rates of 98.1%, 91.2% and 85.6%, respectively, which
were significantly better than OS in patients with a CRS of 3 (all
the risk factors), who achieved 1-, 3- and 5-year OS of 63.5%,
19.6% and 15.7%, respectively (Fig. 2c). Patients with 0 points
had 1-, 3- and 5-year RFS of 88.4%, 73.1% and 53.7%, respec-
tively, whereas patients with a CRS of 3 (all the risk factors) had
1-, 3- and 5-year RFS of 21.2%, 5.7% and 5.7%, respectively
(Fig. 2d).
Table 2 Factors associated with recurrence pattern and death
Variable HR comparison Recurrence beyond MC Recurrence within MC Death without recurrence
HR (95% CI) P-value HR (95% CI) P-value HR P-value
Initial disease beyond MC Within versus beyond 0.34 (0.2–0.56) <0.001 1.42 (0.89–2.27) 0.146 0.76 (0.34–1.67) 0.487
Female Female versus male 0.61 (0.39–0.96) 0.031 0.86 (0.52–1.43) 0.563 1.19 (0.58–2.44) 0.626
Age Per 1-year increase 1 (0.98–1.01) 0.678 1 (0.98–1.02) 0.873 1.03 (1–1.06) 0.042
Prior liver resection Yes versus no 0.95 (0.33–2.74) 0.919 1.06 (0.32–3.48) 0.928 0.7 (0.11–4.43) 0.701
Major resection Major versus minor 1.6 (1.1–2.32) 0.014 0.7 (0.44–1.11) 0.129 1.1 (0.55–2.18) 0.794
Blood loss Per 100-unit increase 1.04 (1.03–1.06) <0.001 0.97 (0.93–1.00) 0.054 0.99 (0.96–1.03) 0.597
α-fetoprotein, ng/ml <200 versus >200 1.48 (0.95–2.28) 0.080 0.97 (0.59–1.6) 0.899 0.67 (0.28–1.56) 0.347
Tumour size Per 1-cm increase 1.11 (1.07–1.16) <0.001 0.96 (0.91–1.01) 0.096 0.99 (0.92–1.06) 0.687
Solitary tumour Multiple versus single 1.87 (1.13–3.1) 0.016 1.14 (0.55–2.36) 0.727 0.75 (0.23–2.4) 0.630
Differentiation Well versus poor or
moderate
0.58 (0.33–1.03) 0.061 1.12 (0.61–2.06) 0.715 1.63 (0.75–3.57) 0.218
Lymphovascular invasion Yes versus no 2.38 (1.64–3.45) <0.001 0.75 (0.47–1.2) 0.230 0.72 (0.35–1.47) 0.367
Microsatellites present Yes versus no 2.51 (1.7–3.71) <0.001 0.92 (0.5–1.67) 0.780 0.68 (0.26–1.79) 0.435
Cirrhosis present Yes versus no 1.16 (0.76–1.78) 0.490 1.08 (0.65−1.79) 0.759 1.9 (0.94–3.85) 0.072
Microsatellites OR multiple
tumours
Yes versus no 2.51 (1.72–3.66) <0.001 0.95 (0.55–1.63) 0.843 0.62 (0.26–1.5) 0.290
Primary liver diseasea 0.173 0.106 0.491
Alcohol-related Yes versus no 0.48 (0.23–1) 2.18 (1.06–4.49) 2.03 (0.79–5.22)
Hepatitis B (Hep B) Hep B versus none 0.7 (0.43–1.12) 1.77 (0.98–3.19) 1.21 (0.51–2.86)
Hepatitis C (Hep C) Hep C versus none 0.65 (0.37−1.14) 2.05 (1.05–3.98) 1.15 (0.41–3.26)
Haemochromatosis (HC) HC versus none 1.02 (0.35−2.95) 0.95 (0.12–7.47) 0
bInitial disease beyond MC Beyond versus within 2.46 (1.48–4.11) <0.001 1.35 (0.82–2.22) 0.241 0.66 (0.29–1.48) 0.312
bMicrosatellites OR
multiple tumours
Yes versus no 2.28 (1.52–3.4) <0.001 1.01 (0.58–1.76) 0.965 0.6 (0.24–1.47) 0.264
bLymphovascular invasion Yes versus no 2.22 (1.52–3.23) <0.001 0.8 (0.48–1.32) 0.380 0.69 (0.33–1.43) 0.319
Rows in bold are to distinguish from the above rows as the important multivariate analysis part that leads to the clinical risk score (CRS).
aPatients with non-alcoholic steatohepatitis and combined Hep B/C are excluded.
bMultivariate analysis of risk factors associated with recurrence pattern.
95% CI, 95% confidence interval; HR, hazard ratio; MC, Milan criteria.
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Discussion
Liver resection and OLT form the foundation of HCC treatment.
Although LR is the preferred treatment modality for resectable
tumours in patients with preserved liver function, high recurrence
rates remain problematic.25 Liver transplantation, by contrast, is
considered the gold standard treatment in patients with cirrhosis
with tumours within the MC, but is limited by organ availability,
tumour progression while on the transplant waiting list and the
problems inherent in the use of lifelong immunosuppression.3
The roles of LR and OLT in HCC are continuously evolving, and
there is ongoing debate with regard to the optimal treatment
strategy in patients with mild cirrhosis and early HCC.4,26 The
controversy between LR and OLT concerns the group of patients
with HCC within the MC and limited underlying parenchymal
disease (e.g. Child–Pugh class A/low B liver cirrhosis).25,27 Many
studies have tried to address this question; unfortunately, because
of the retrospective nature and the inherent biases of these studies,
cohorts of LR and OLT patients are often not equivalent in terms
of clinicopathological characteristics and no strong conclusions
have been drawn. A meta-analysis looking at 62 studies comparing
LR and OLT in the treatment of HCC reported similar 1-year OS,
but patients submitted to OLT achieved significantly better 3- and
5-year OS (when organs were available); the authors also found
that disease-free survival and recurrence were similar in early
HCC patients with Child–Pugh class A cirrhosis.28 Another meta-
analysis by Dhir et al., which looked at 24 studies with a total of
1763 patients with HCC within the MC who were treated with LR
versus OLT, echoed the survival benefit of OLT over LR, but this
survival advantage disappeared when intention-to-treat analysis
was used.29
The recurrence of HCC after LR remains a major limitation of
resection in comparison with OLT.25 The strategy of using upfront
LR in all resectable HCC in patients with normal or limited liver
disease, followed by ST as a back-up option when the tumour
recurs, is feasible. It combines the benefits of a good quality of life
after LR with survival outcomes similar to those in patients who
undergo initial OLT, the lack of a waiting time/dropout factor, is
potentially curative, implies less need for longterm immunosup-
pression, and, perhaps most importantly from a medicosocial
standpoint, allows for the more optimal use of donor livers,
thereby reserving this scarce resource for patients with no alter-
native options.11,15 We have previously reported our experience in
relation to patterns of recurrence of HCC and have identified
tumour size and vascular invasion as predictors of recurrence.30 In
a subsequent study, we reported size, vascular invasion and
satellitosis to be important in nomograms for recurrence and
survival.31 Many other studies and systematic reviews have simi-
larly emphasized the importance of clinicopathological features,
such as tumour size and number, time to recurrence, and the
presence of micro- or macrovascular invasion as independent
predictive factors for recurrence and survival.32–37 Some studies
have specifically identified microvascular invasion, poor differen-
tiation, tumour size of >6 cm and portal vein invasion as predic-
tors of the recurrence of HCC beyond the MC. In the present
study, initial disease beyond the MC, the presence of
microsatellites or multiple tumours and lymphovascular invasion
were also found to be independent predictors of the recurrence of
HCC beyond the MC. However, the present analyses have failed to
identify any risk factors associated with recurrence within the MC
(Table 2).
Some centres have advocated prophylactic, pre-emptive listing
for ST (i.e. before recurrence is detected), especially in patients
with a high risk profile (vascular invasion and/or additional
nodules) as recommended by the Barcelona Clinic Liver Cancer
(BCLC) group, whereas others have adopted a wait-and-see
approach, reserving ST only when recurrences are detected.14,38–41
There is no consensus on the timing of ST after LR. Performing
a prophylactic ST before any evidence of tumour recurrence
eliminates the chance of recurrence beyond the MC, but subjects
the patient to another major procedure and its attendant risks
while limiting the benefits of the initial LR in patients without
recurrence. It also imposes a significant burden on the limited
pool of donated organs. In the present study, the majority of
patients would not have benefited from a prophylactic ST: by 5
years post-surgery, only 46% of patients with initial tumours
beyond the MC and 20% of patients with initial tumours within
the MC had recurrence beyond the MC (Fig. 3). Conversely, the
proponents of pre-emptive ST would argue that almost half of
patients with HCC recurrence following LR will not make it to
ST as a result of various transplant eligibility considerations,
including patient factors such as advanced age, patient refusal
and tumour factors such as recurrent disease beyond the MC.11
In the USA, the concept of prophylactic transplant post-LR is not
applicable because no tumour exception points can be allocated
to patients without recurrence after a potentially curative HCC
resection.
The present study analysed the factors that can help predict the
pattern of HCC recurrence, specifically recurrence beyond the
MC, as this group of patients is disadvantaged by the loss of
opportunity for OLT, especially those in whom initial tumours
were within the MC (and who were thus eligible for initial OLT).
By 5 years, 19.9% of patients with initial disease within the MC
experienced recurrence beyond the MC, which is similar to the
rates of 12–27% reported by other groups.11,21,22 Most of the other
studies reported on populations of patients with cirrhosis and
tumours within the MC.11 However, the present study examined
the potential for ST in a population of patients with advanced
tumours arising largely in non-cirrhotic liver, and focused on
recurrence patterns in relation to preoperative MC status and
clinicopathological risk factors. The present findings demonstrate
that a significant percentage of patients who harboured tumours
within or beyond the MC remained disease-free or experienced
recurrences within the MC, and therefore could be considered for
ST. Furthermore, the incorporation of the risk factors into the MC
enhanced the identification of patients with unfavourable tumour
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biology who might potentially benefit from early referral to a
transplant centre for consideration for ST after LR rather than the
blind adoption of a wait-and-see policy. Other studies have also
suggested that the strategy of utilizing pathological factors found
at resection to offer ST is feasible.11,13 Fuks et al. found that adverse
histopathological characteristics (vascular invasion, satellites,
tumour size of >3 cm, poor tumour differentiation and liver cir-
rhosis) were associated with non-transplantability at recurrence
and that these characteristics might be used to better select appro-
priate patients for ST.11 It should be noted that in the cohort
reported by Fuks et al.,11 all patients harboured tumours within
the MC and 89% had cirrhosis, whereas the present study com-
prised patients with advanced disease and healthier normal livers
(69% beyond the MC and 24% with cirrhosis). Nonetheless, a
significant proportion of recurrences in the present series were
within the MC, even in patients with advanced disease initially
beyond the MC; therefore, it is not surprising that others have
found that in the context of small, transplantable HCC lesions, a
significant proportion of patients experienced no recurrence or
recurrence within criteria for transplantation.15,18 In patients with
a high likelihood of recurrence beyond the MC, the issue of
whether they would be better served with upfront OLT or would
not benefit greatly from OLT because of underlying aggressive
tumour biology is controversial. Furthermore, it is unclear
whether patients with a high likelihood of beyond-MC recurrence
would be better served by upfront OLT or whether the underlying
aggressive tumour biology would limit the benefit of this
approach. There is limited evidence to date supporting either
theory.6,28 This theoretical debate is further confounded by data
showing that the yield of OLT over LR is directly related to waiting
time.15,42
The CRS established in the present study is useful for estimating
patterns of recurrence of HCC; it incorporates the established risk
factors and provides a simple clinical tool that is applicable to
patients undergoing resection. It considers a patient’s
clinicopathological variables and can provide more accurate pre-
dictions of post-resection recurrence than those based solely on
clinical judgement or the classification of patients into broad
high- and low-risk groups. The CRS will need to be further vali-
dated in larger studies.
The limitations of the present study relate to its retrospective
nature and the fact that the study population was derived from a
single institution. As a comprehensive cancer centre, this institu-
tion does not have a solid organ transplantation programme and
thus lacks a comparable cohort of patients with HCC who can be
listed for OLT at the time of initial presentation. For the same
reason, detailed information on ST rates in the present cohort is
not available. Nonetheless, the decision-making process at this
institution is based on consensus achieved during weekly multi-
disciplinary conferences and suitable patients for whom OLT is
considered a better option are referred to a liver transplantation
centre. Additionally, the database at this institution is prospec-
tively maintained, which minimizes the occurrence of errors in its
data. There is an element of lead time bias as it is possible that the
earlier detection of recurrence through frequent and closer sur-
veillance scans in patients with disease of a worse prognosis might
bias the effects of some prognostic factors, causing them to appear
more unfavourable. However, follow-up was fairly uniform in this
cohort and hence this effect was negligible and is not expected to
alter the present results and conclusions.
In summary, in a modern series of LR with curative intent for
advanced HCC in a largely non-cirrhotic population, a significant
proportion of patients were found to experience recurrence
within the MC or to remain disease-free, and thus were eligible for
ST. The incorporation into the MC of lymphovascular invasion
and the presence of microsatellitosis or multiple tumours further
enhanced their prognostic role and should be taken into account
when patients are considered for ST at the time of surgical resec-
tion and to guide closer surveillance post-resection.
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